Tefibazumab

Tefibazumab is a monoclonal antibody that was designed for the treatment of Staphylococcus aureus infections. It was developed by Inhibitex, a biopharmaceutical company that was later acquired by Bristol-Myers Squibb.

History[edit | edit source]

Tefibazumab was developed in the early 2000s by Inhibitex, a company that specialized in the development of antibacterial and antiviral drugs. The drug was designed to target and neutralize Staphylococcus aureus, a common bacterium that can cause a variety of infections.

Mechanism of Action[edit | edit source]

Tefibazumab is a monoclonal antibody, a type of drug that is designed to bind to a specific target. In the case of tefibazumab, the target is a protein on the surface of Staphylococcus aureus cells. By binding to this protein, tefibazumab can prevent the bacteria from adhering to human cells, thereby preventing infection.

Clinical Trials[edit | edit source]

Tefibazumab underwent several rounds of clinical trials in the mid-2000s. These trials were designed to test the safety and efficacy of the drug in patients with Staphylococcus aureus infections. However, the results of these trials were mixed, and the development of tefibazumab was eventually discontinued.

Acquisition by Bristol-Myers Squibb[edit | edit source]

In 2012, Inhibitex was acquired by Bristol-Myers Squibb, a large pharmaceutical company. As part of this acquisition, Bristol-Myers Squibb gained the rights to tefibazumab. However, as of 2021, the drug has not been further developed or brought to market.